Results 1 to 10 of about 2,202,582 (329)
LLM-Enhanced Multimodal Framework for Drug–Drug Interaction Prediction [PDF]
Background: Drug–drug interactions (DDIs) involve pharmacokinetic or pharmacodynamic changes that occur when multiple drugs are co-administered, potentially leading to reduced efficacy or adverse effects.
Song Im, Younhee Ko
doaj +2 more sources
MDG-DDI: multi-feature drug graph for drug-drug interaction prediction [PDF]
Background Drug–drug interactions (DDIs) frequently occur in combination therapy and may cause adverse effects or reduced efficacy. Existing computational approaches often fail to capture both the semantic information in drug sequences and the structural
Wenjun Li +4 more
doaj +2 more sources
Graph neural network-based drug-drug interaction prediction [PDF]
With the growing variety of pharmacological compounds and the increasing need for polypharmacy, accurately predicting drug-drug interactions (DDIs) is essential to ensure both treatment efficacy and patient safety. Beneficial DDIs can enhance therapeutic
Khushnood Abbas +5 more
doaj +2 more sources
Pharmacist Intervention Models in Drug-Drug Interaction Management in Prescribed Pharmacotherapy. [PDF]
Samardžić I +4 more
europepmc +3 more sources
Although the use of excipients is widespread, a thorough understanding of the drug interaction potential of these compounds remains a frequent topic of current research.
Savannah J. McFeely +4 more
doaj +1 more source
Telmisartan (TEL, an antihypertensive drug) belongs to Class II of the Biopharmaceutical Classification System (BCS) because of its poor aqueous solubility.
Bhupendra Raj Giri +5 more
doaj +1 more source
Effect of Lactic Acid Bacteria on the Pharmacokinetics and Metabolism of Ginsenosides in Mice
This study aims to investigate the effect of lactic acid bacteria (LAB) on in vitro and in vivo metabolism and the pharmacokinetics of ginsenosides in mice.
Ji-Hyeon Jeon +5 more
doaj +1 more source
Candesartan cilexetil (CC), a prodrug and highly effective antihypertensive agent, is a poorly soluble (BCS Class II) drug with limited bioavailability.
Surendra Poudel, Dong Wuk Kim
doaj +1 more source
Fimasartan, amlodipine, and hydrochlorothiazide are commonly used in combination therapies as antihypertensive drugs. This study aimed to develop and validate an analytical method for fimasartan, its active and major metabolite fimasartan-amide ...
So-Yeon Jeon +6 more
doaj +1 more source
NOACs: drug–drug interactions [PDF]
We commend Fralick and colleagues for their article on drug interactions with rivaroxaban.[1][1] All novel oral anticoagulants (NOACs) were introduced as at least noninferior (in some cases superior) to warfarin.
Bartosz, Hudzik +2 more
openaire +2 more sources

